-

Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board

original Robert R. Ruffolo, Ph.D. (Photo: Business Wire)

Robert R. Ruffolo, Ph.D. (Photo: Business Wire)

PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.

“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."

Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.

About Neuraptive

Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.

Contacts

IR@neuraptive.com
or
+1-484-787-3203

Industry:

Neuraptive Therapeutics, Inc.

Details
Headquarters: Wayne, PA
CEO: Robert (Bob) Radie
Employees: 8
Organization: PRI
Release Versions
EnglishSpanishPortugueseGermanFrenchItalian (Summary)Dutch (Summary)Chinese TraditionalChinese SimplifiedJapanese

Contacts

IR@neuraptive.com
or
+1-484-787-3203

Social Media Profiles
Client Twitter
More News From Neuraptive Therapeutics, Inc.

Neuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. Louis

CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a clinical-stage biotech company focused on peripheral nerve injuries, announced today that it has secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device. Developed by researchers at WashU Medicine in collaboration with Northwestern University, the technology delivers targeted electrical pulses to damaged nerves to speed up regeneration. The device is fully...

Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization

CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. W...

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial...
Back to Newsroom